[{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oncolytics Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||CD8 T-cell","graph1":"Oncology","graph2":"Phase II","graph3":"Oncolytics Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncolytics Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncolytics Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amcenestrant","moa":"||Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Palbociclib","moa":"||CDK6\/cyclin D1 | Cyclin-dependent kinase 4\/cyclin D1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Agendia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase III","graph3":"Agendia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Agendia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agendia \/ Inapplicable"},{"orgOrder":0,"company":"UNICANCER","sponsor":"Agendia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"UNICANCER","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"UNICANCER \/ Agendia","highestDevelopmentStatusID":"8","companyTruncated":"UNICANCER \/ Agendia"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Alisertib","moa":"||Serine\/threonine-protein kinase Aurora-A","graph1":"Oncology","graph2":"Phase II","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Enteric Coated","sponsorNew":"Puma Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Puma Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Spanish Breast Cancer Research Group","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"Spanish Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spanish Breast Cancer Research Group \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Spanish Breast Cancer Research Group \/ Eli Lilly"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Eli Lilly | Cancer Prevention Research Institute of Texas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"UT Southwestern Medical Center \/ Eli Lilly | Cancer Prevention Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"UT Southwestern Medical Center \/ Eli Lilly | Cancer Prevention Research Institute of Texas"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"Novartis Pharmaceuticals Corporation | Vestre Viken Hospital Trust","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akershus University Hospital \/ Novartis Pharmaceuticals Corporation | Vestre Viken Hospital Trust","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ Novartis Pharmaceuticals Corporation | Vestre Viken Hospital Trust"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSPC ZhongQi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSPC ZhongQi \/ Inapplicable"},{"orgOrder":0,"company":"Onconova Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Narazaciclib","moa":"||ARK5\/CDK4\/CDK6\/CSF-1R\/FLT3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Onconova Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Onconova Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Onconova Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avenzo Therapeutics","sponsor":"New Enterprise Associates","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"AVZO-021","moa":"||CDK2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Avenzo Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"Avenzo Therapeutics \/ New Enterprise Associates","highestDevelopmentStatusID":"7","companyTruncated":"Avenzo Therapeutics \/ New Enterprise Associates"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Onapristone","moa":"||Progesterone receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Context Therapeutics \/ Menarini","highestDevelopmentStatusID":"8","companyTruncated":"Context Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Yongsheng Wang","sponsor":"Jiangsu Hengrui Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase IV","graph3":"Yongsheng Wang","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yongsheng Wang \/ Jiangsu Hengrui Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Yongsheng Wang \/ Jiangsu Hengrui Medicine"},{"orgOrder":0,"company":"Nicholas Macklon","sponsor":"Gedeon Richter | Igenomix","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Undisclosed","graph2":"Phase II","graph3":"Nicholas Macklon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nicholas Macklon \/ Gedeon Richter | Igenomix","highestDevelopmentStatusID":"8","companyTruncated":"Nicholas Macklon \/ Gedeon Richter | Igenomix"},{"orgOrder":0,"company":"Gynuity Health Projects","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Gynuity Health Projects","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gynuity Health Projects \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gynuity Health Projects \/ Inapplicable"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Egymedicalpedia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Context Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Context Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Context Therapeutics"},{"orgOrder":0,"company":"Laboratorios Farmaceuticos Rovi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratorios Farmaceuticos Rovi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorios Farmaceuticos Rovi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Farmaceuticos Rovi \/ Inapplicable"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Ain Shams University","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Letrozole","moa":"Cytochrome P450 19A1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Egymedicalpedia \/ Ain Shams University","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ Ain Shams University"}]
Find Clinical Drug Pipeline Developments & Deals for Femara, Letrozole
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target